A practical reference on Cyclic AMP: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
However, unlike tramadol, tapentadol exerts minimal influence on serotonin reuptake and is approximately 2–3 times more potent as an opioid. Tapentadol also lacks active metabolites, which distinguishes it from tramadol and may contribute to a more predictable pharmacokinetic profile.
== Further reading == Savulescu, Julian; Bostrom, Nick (2009). Human enhancement. Oxford: Oxford University Press. ISBN 978-0-19-929972-0. Savulescu, Julian; ter Meulen, Ruud; Kahane, Guy (2011). Enhancing human capacities. Chichester: Wiley-Blackwell. ISBN 978-1-4051-9581-2. Michael Bess (2015). Our Grandchildren Redesigned: Life in the Bioengineered Society of the Near Future. Beacon Press. ISBN 978-0-8070-5217-4. Bateman, Simone; Gayon, Jean; Allouche, Sylvie; Goffette, Jérôme; Marzano, Michela (2015). Inquiring into Human Enhancement: Interdisciplinary and International Perspectives (1 ed.). London: Palgrave Macmillan. ISBN 978-1-137-53006-6. Edwards, Gary (2016). "Enhancement". Encyclopedia of Global Bioethics. Springer International Publishing. pp. 1121–1130. doi:10.1007/978-3-319-09483-0_172. ISBN 978-3-319-09483-0. Jotterand, Fabrice; Ienca, Marcello (2024). The Routledge Handbook of the Ethics of Human Enhancement. New York: Routledge. ISBN 978-0-367-61579-6.
=== ICD-11 === The eleventh revision of the International Classification of Diseases, commonly referred to as ICD-11, conceptualizes diagnosis somewhat differently. ICD-11 first distinguishes between problems with psychoactive substance use ("Disorders due to substance use") and behavioral addictions ("Disorders due to addictive behaviours"). With regard to psychoactive substances, ICD-11 explains that the included substances initially produce "pleasant or appealing psychoactive effects that are rewarding and reinforcing with repeated use, [but] with continued use, many of the included substances have the capacity to produce dependence. They have the potential to cause numerous forms of harm, both to mental and physical health." Instead of the DSM-5 approach of one diagnosis ("Substance Use Disorder") covering all types of problematic substance use, ICD-11 offers three diagnostic possibilities: 1) Episode of Harmful Psychoactive Substance Use, 2) Harmful Pattern of Psychoactive Substance Use, and 3) Substance Dependence.
Insecticides are pesticides used to kill insects. They include ovicides and larvicides used against insect eggs and larvae, respectively. The major use of insecticides is in agriculture, but they are also used in home and garden settings, industrial buildings, for vector control, and control of insect parasites of animals and humans. Acaricides, which kill mites and ticks, are not strictly insecticides, but are usually classified together with insecticides. Some insecticides (including common bug sprays) are effective against other non-insect arthropods as well, such as scorpions, spiders, etc. Insecticides are distinct from insect repellents, which repel but do not kill.
Consultancy firm Cornwall Insight forecasts that energy bills will fall by 16% in April, saving the average household around £300 a year. The UK and US launch fresh air strikes against Houthi targets in Yemen. The UK's Charity Commission launches an investigation into antisemitic speeches given by members of the Iranian Revolutionary Guard to students at a UK-based Islamic charity, which included chants of "death to Israel". 23 January Data from the Office for National Statistics indicates government borrowing in December was at £7.8bn, a fall from £16.2bn in December 2022, and the lowest since 2019. Sunak tells Parliament the UK will not hesitate to launch further air strikes against Houthi rebels if they continue to attack shipping targets in the Red Sea, but does not seek confrontation with the group. Most of the UK is placed under a Met Office yellow weather warning for high winds as Storm Jocelyn arrives. 2023 Nottingham attacks: Valdo Calocane admits three counts of manslaughter and three of attempted murder. 24 January Sir Patrick Sanders, the Chief of the General Staff, warns that the UK should train a "citizen army" ready to fight a war on land in the future, highlighting Russia as a potential threat and the steps being taken by other European countries to put their populations on a "war footing". Ofcom publish plans to reform Royal Mail with the options of reducing postal deliveries from six to five or three days a week, or delaying the time the service takes to fulfil its deliveries.
Sources: en.wikipedia.org
== Healthcare == UPMC Children's Hospital of Pittsburgh Community Health Partnerships, Scotland Certified Health Physicist, United States, a specialist in radiation protection and safety Centre for Health Protection, an agency of Hong Kong Cricohyoidopexy, a surgical procedure
=== Financing === In May 2016, Cerebras raised $27 million in a series A round led by Benchmark, Foundation Capital and Eclipse Ventures. In December 2016, the company raised a series B round led by Coatue Management. In January 2017, it raised a series C round led by VY Capital. In November 2018, Cerebras raised $88 million in a series D round, making the company a unicorn. Investors in this round included Altimeter, VY Capital, Coatue, Foundation Capital, Benchmark, and Eclipse. In November 2019, Cerebras raised $270 million in a series E round at a valuation of $2.4 billion. In November 2021, Cerebras raised $250 million in a Series F round, valuing the company at over $4 billion and bringing its total financing to $720 million. The Series F financing round was led by Alpha Wave Ventures and Abu Dhabi Growth Fund (ADG). In July, August, and September 2024, the company raised $85 million in a series F-1 round, selling shares for $14.66 each. In September 2025, the company raised $1.1 billion in a Series G round, selling shares for $36.23 each, or a valuation of $8.1 billion. In January 2026, the company raised $1.0 billion in a Series H round, selling shares for $89.01 each. In this round, Benchmark invested $225 million, while Alpha Wave and funds managed by Fidelity Investments each invested $100 million. On May 14, 2026, the company became a public company via the largest U.S. technology initial public offering since 2019, raising $5.55 billion by selling 30 million shares at $185 each and opening on Nasdaq at $350, valuing the company at $95 billion.
guide RNA (gRNA) Also single guide RNA (sgRNA). A short single-stranded RNA oligonucleotide which complexes with Cas endonucleases and, by annealing to a specific complementary sequence in a DNA molecule, serves to "guide" these proteins to viral DNA introduced by foreign pathogens, which can then be digested and degraded as part of an adaptive immune defense employed by bacteria and archaea. Custom-made guide RNAs are designed by scientists to target specific genomic loci in CRISPR-Cas gene editing.
=== Secret peace discussions, opposition to troop withdrawals === In June 1969, the former Defense Secretary Clark Clifford published an article in Foreign Affairs calling for the withdraw of 100,000 U.S. troops from Vietnam by the end of 1969 and all by the end of 1970. Influenced by Laird, Nixon announced the immediate withdraw of 25,000 U.S. troops from Vietnam, saying: "I would hope that we could beat Mr. Clifford's timetable". Kissinger was opposed to the withdrawal, which he predicted would mean the immediate collapse of South Vietnam. On 4 August 1969, Kissinger met secretly with Xuân Thủy at the Paris apartment of Jean Sainteny to discuss peace. Sainteny was a former French colonial official sympathetic to Vietnamese nationalism who had offered to serve as an honest broker. Kissinger had been hoping to see Tho rather than Thuy. Kissinger repeated the American offer of "mutual withdrawal" of U.S. and North Vietnamese forces from South Vietnam, which Thủy rejected, while Thủy demanded a new government in Saigon, which Kissinger rejected. Kissinger had a low opinion of North Vietnam, saying "I can't believe that a fourth-rate power like North Vietnam doesn't have a breaking point". Kissinger was opposed to the strategy of Vietnamization, expressing some doubt about the ability of the ARVN (Army of the Republic of Vietnam-i.e. the South Vietnamese Army) to hold the field, causing much tension with Defense Secretary Laird who was deeply committed to Vietnamization. In September 1969, Kissinger, in a memo, advised Nixon against "de-escalation", saying that keeping U.S.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.